IN8bio (INAB) investor relations material

Platform and strategic thesis

• Clinical-stage programs use gamma-delta T cells for oncology and autoimmune disease, aiming to coordinate immune activity with more selective targeting.

• Gamma-delta T cells make up 1%-5% of healthy immune cells; their proposed advantage is frontline target recognition and signaling to other immune cells.

• Strategy expanded into T-cell engagers as cell therapy sentiment weakened; management sees engagers as more aligned with pharma’s off-the-shelf dosing and commercial distribution models.

Autoimmune T-cell engager

• INB-619 links CD19 on B cells to the gamma-delta T-cell receptor and includes an expansion domain intended to increase gamma-delta T-cell numbers.

• In a blood-culture experiment, CD19-positive cells rose from 0.77% to 66% after adding a leukemia cell line, then fell below 1% with INB-619.

• In three healthy-donor samples, target-killing cytokines showed a dose response while IL-6 remained flat; management said gamma-delta T cells do not secrete IL-6.

• In vitro comparisons showed B-cell depletion equivalent to or better than blinatumomab and mosunetuzumab across tested doses, with a 1-2 day delay attributed to gamma-delta T-cell expansion.

• At 5,000 pM, INB-619 produced IL-6 levels comparable to mosunetuzumab at 28 pM; management cited this 178x dose difference as evidence of a wider potential therapeutic window.

• First animal data are expected this fall; management cited potential for deep B-cell depletion and reduced infection risk, while noting in vivo proof of concept remains a key milestone.

Glioblastoma clinical program

• Phase I/II treatment adds gamma-delta T-cell injections through an intracranial catheter during maintenance chemotherapy; the study ran at UAB, Ohio State, Moffitt and Cleveland Clinic.

• Published Phase I data showed median progression-free survival of 13 months versus 6.6 months and median overall survival of 19.5 months versus 13.2 months; OS median had not been reached as of May 15.

• Management reported doubled time to progression, no major safety concerns and no observed cases of cytokine release syndrome to date.

• FDA discussions on a potential registrational path are expected this year, with an update planned later this year; management expects to provide updated OS data at a fall meeting, historically SNO in November.